Key Takeaways:
- FDA holds critical public hearing today on the Priority Voucher program that approved Foundayo in record 50 days
- The controversial program has accelerated 7 drug approvals since launch, including the first oral GLP-1 pill
- Stakeholders are raising concerns about transparency and selection criteria for ultra-fast reviews
Today marks a pivotal moment for the future of drug approvals in America as the FDA holds a public hearing at its White Oak headquarters to gather feedback on the Commissioner's National Priority Voucher (CNPV) pilot program. The hybrid meeting, running from 1-4 PM ET, comes amid growing scrutiny of a program that has revolutionized how quickly treatments reach patients.
The Program That Changed Everything
The Commissioner's National Priority Voucher Program offers an unprecedented opportunity to reduce drug and biologic review times from 10-12 months to 1-2 months. Since its launch in June 2025, the program has delivered on that promise in spectacular fashion.
Most notably for the GLP-1 community, the FDA approved Foundayo (orforglipron) in 50 days after filing, marking the first new molecular entity approved under the program and the fastest approval of an NME since 2002. This once-daily oral pill that delivers meaningful weight loss can be taken any time of day without food or water restrictions, representing a major advancement in convenience for people managing obesity.
Seven approvals have now been granted under the CNPV program, including gene therapies for genetic hearing loss and treatments for rare cancers. But it's the GLP-1 approval that has drawn the most attention, given the massive demand for these medications alongside existing options like semaglutide injection and tirzepatide.
Growing Transparency Concerns
Despite the program's success in accelerating approvals, there has been considerable controversy regarding the CNVP program and the transparency of the selection process for candidates for the vouchers. Critics are questioning how the FDA selects which drugs qualify for this ultra-fast pathway and whether the process gives unfair advantages to certain companies.
The public hearing will seek feedback about the program's eligibility criteria, the voucher selection processes, sponsor responsibilities, pre-submission requirements, FDA review procedures, the role of the CNPV Review Council, and other aspects of program implementation. These are exactly the areas where stakeholders want more clarity.
The timing is significant. Requests to speak were due by April 24, and the FDA is soliciting written comments until June 29, suggesting the agency is genuinely seeking input that could reshape how the program operates.
Impact on GLP-1 Access and Pricing
For people exploring GLP-1 medications, the CNPV program represents both promise and concern. On one hand, it enabled Foundayo to reach the market nearly 10 months ahead of schedule. Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card, while individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose.
This pricing is competitive with many telehealth providers offering compounded versions, but with the added security of FDA approval. However, the selection process raises questions about which future GLP-1 innovations might receive similar fast-track treatment.
When comparing treatment costs, the rapid approval of Foundayo has created new options in a market where many people face long wait times or high prices for existing medications. The oral format eliminates the need for injections, which could reduce barriers for people hesitant about needle-based treatments.
What Stakeholders Are Saying
FDA panelists will include subject matter experts from the Office of the Commissioner, the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Oncology Center of Excellence. This high-level representation shows how seriously the FDA is taking the feedback session.
FDA Commissioner Martin Makary has stated that "this approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners". But industry observers want assurance that this speed doesn't come at the expense of fairness or scientific rigor.
The FDA has emphasized that pre-market applications selected for the program are subject to the same statutory and regulatory requirements for approval, and the agency may also grant accelerated approval if the product meets applicable legal requirements.
What This Means for You
Today's hearing could significantly impact how quickly future GLP-1 medications reach the market. If the FDA maintains or expands the program, we might see more treatments like oral formulations, longer-acting injections, or combination therapies approved in record time.
For people currently weighing their options, this program represents a potential pathway to more approved choices at competitive prices. However, the controversy around selection criteria means the benefits might not be evenly distributed across all promising treatments.
If you're considering GLP-1 treatment, you can explore options through local clinics that now have access to this new oral medication alongside traditional injectable options. The expanded choices mean you can work with providers to find the approach that fits your lifestyle and budget.
The hearing is being live-streamed on the FDA's YouTube channel, and a recording will be available afterward. If you're interested in having a voice in how these critical medications are approved, written comments are still being accepted through June 29.
Sources
- FDA Schedules Public Meeting on Commissioner's National Priority Voucher Pilot Program - FDA press release announcing today's hearing
- FDA Approves First New Molecular Entity Under National Priority Voucher Program - FDA announcement of Foundayo approval
- Commissioner's National Priority Voucher Pilot Program - FDA program overview and background